Senolytic CAR T Cell Therapy: A Living Drug Strategy for Aging and Cancer

Senolytic CAR T cell therapy is an emerging precision immunotherapy that uses engineered immune cells to eliminate senescent cells, aged, dysfunctional cells that accumulate in tissues and drive chronic disease. Building on the success of CAR T cells in cancer, this approach adapts the same technology to target a universal marker of senescence: the urokinase-type plasminogen activator receptor (uPAR). Pioneered by researchers at Memorial Sloan Kettering Cancer Center and Cold Spring Harbor Laboratory, this strategy has demonstrated unprecedented durability, with a single infusion showing long-lasting effects in preclinical models . This essay explores the science of senescence, the design of uPAR-targeting CAR T cells, the evidence for their efficacy in age-related diseases and cancer, the clinical translation efforts, and the challenges that remain.

---

1. Introduction: The Aging Cell Problem

Cellular senescence is a stress response program characterized by a stable cell cycle arrest. Physiologically, it serves as a tumor-suppressive mechanism that prevents the expansion of premalignant cells and plays a beneficial role in wound healing. Pathologically, the aberrant accumulation of senescent cells generates an inflammatory milieu known as the senescence-associated secretory phenotype (SASP), which leads to chronic tissue damage and contributes to diseases such as liver and lung fibrosis, atherosclerosis, diabetes, and osteoarthritis .

Most efforts to develop senolytic therapies have focused on small-molecule drugs that target poorly defined molecular dependencies in senescent cells, requiring repeated administration. CAR T cells offer a fundamentally different approach. As "living drugs," they can persist in the organism and exert their effects over years after a single administration, much as they do in cancer patients cured of disease .

---

2. The Central Target: uPAR

The urokinase-type plasminogen activator receptor (uPAR) is a cell-surface protein that is broadly induced during senescence. It serves as an ideal target for senolytic CAR T cells because it is selectively overexpressed on the surface of senescent cells across multiple tissues .

Meta-analysis of senescence-focused and cancer datasets has confirmed uPAR's prominence in multiple tumor types exhibiting senescence features, validated through patient tissue microarrays. This broad expression pattern across diverse pathological contexts makes uPAR a promising target for a "cancer-agnostic" therapeutic approach .

One important consideration is that uPAR is detectable at low levels in some normal tissues, including the lungs, a subset of myocytes, and innate immune cells. This raises concerns about potential off-target effects that require careful management through dosing optimization and antigen selection .

---

3. The "One-Two Punch" Strategy

A particularly innovative application of senolytic CAR T cells involves combining them with senescence-inducing therapies. Chemotherapy, targeted therapy, and radiation can induce therapy-induced senescence (TIS) in cancer cells, creating an immunogenic state that makes them vulnerable to CAR T cell attack .

This "one-two punch" strategy works as follows. First, conventional therapy pushes cancer cells into senescence. Second, CAR T cells targeting the senescence marker uPAR are administered to clear the senescent cells, which might otherwise persist and contribute to tumor recurrence .

The potential synergy is significant. Senolytic CAR T cells can eliminate the residual senescent cells that often survive chemotherapy, potentially eradicating minimal residual disease and preventing relapse . This approach has shown promise in 'immune-cold' tumors such as ovarian and pancreatic cancers, where senescence induction enhances the efficacy of CAR T cells .

---

4. Mechanisms of Action

Selective Targeting and Clearance

Senolytic CAR T cells migrate to areas of senescence and infiltrate senescent tissues. The binding of the CAR to uPAR triggers an intracellular signaling cascade that elicits T cell activation, proliferation, and effector functions, resulting in the lysis of senescent cells. Elimination of these cells subsequently restores tissue homeostasis and function .

Mitochondrial Priming as a Predictive Checkpoint

Recent research has revealed a crucial barrier: therapy-induced senescent cancer cells are globally less primed for apoptosis than their proliferating precursors. This means they are more resistant to cell death signals, potentially limiting the efficacy of CAR T cells. However, senescent cells exhibit conserved, druggable dependence on specific BCL-2 family members. This "inherited" mitochondrial memory can be assessed using BH3 profiling, a functional assay that measures proximity to the mitochondrial apoptotic threshold. This could serve as a companion diagnostic to personalize CAR-based immunosenolytic therapy .

Durability and Memory Response

CAR T cells can persist and exert their effects over time. In preclinical studies, a single administration of uPAR CAR T cells resulted in long-term expansion and memory response, presumably owing to increased antigen stimulation as the frequency of target uPAR-positive cells increases over time. This persistence allows for both therapeutic and prophylactic effects .

---

5. Efficacy in Preclinical Models

Age-Related Metabolic Dysfunction

In naturally aged mice (18-20 months old), a single infusion of uPAR CAR T cells reduced senescent cell burden in the pancreas, liver, and adipose tissue, and decreased plasma levels of pro-inflammatory cytokines. Treated mice showed significantly decreased fasting glucose levels, improved glucose tolerance, and enhanced pancreatic beta cell function—indicative of improved metabolic health. Furthermore, they demonstrated improvements in exercise capacity at 2.5 months after treatment compared to pretreatment levels .

Prophylactic Effects in Young Mice

Remarkably, a single dose of uPAR CAR T cells administered to young mice (3 months old) prevented age-related metabolic decline. CAR T cells persisted in the spleen and liver for 12 months, and the treated mice had significantly lower fasting glucose levels and better exercise capacity at 9 months of age compared to controls. This suggests that early intervention could delay or prevent features of age-dependent metabolic dysfunction .

Liver Fibrosis and Solid Tumors

uPAR CAR T cells have shown efficacy in reversing liver fibrosis in chemically or diet-induced mouse models, restoring tissue homeostasis. In cancer models, they extend the survival of mice with lung adenocarcinoma treated with senescence-inducing drug combinations and demonstrate potent anti-tumor activities across a range of cancer types including lung, pancreas, and ovarian cancers .

---

6. Clinical Translation

Logic-Gated CAR NK Cells

Senti Biosciences has developed SENTI-202, a first-in-class "logic-gated" CAR NK cell therapy for relapsed/refractory acute myeloid leukemia (AML). This therapy uses an "OR" gate to target cells expressing CD33 OR FLT3, combined with a "NOT" gate to protect healthy hematopoietic stem cells expressing EMCN. This design allows selective killing of AML blasts and leukemic stem cells while sparing healthy bone marrow stem cells. As of October 2025, 20 patients have been dosed, with a 50% overall response rate and a 42% complete remission rate at the recommended Phase 2 dose .

In Vivo CAR T Cell Engineering

Innovative delivery platforms are being developed to simplify CAR T cell manufacturing. One approach uses cardiolipin-mimic lipid nanoparticles that deliver mRNA encoding uPAR CARs directly to T cells in vivo, without the need for antibody modification. This has shown efficacy in treating uPAR-related liver fibrosis and rheumatoid arthritis in preclinical models, offering a streamlined alternative to ex vivo therapy .

---

7. Challenges and Limitations

Off-Target Toxicity

uPAR is detectable at low levels in the lungs and other normal tissues, raising concerns about potential off-target effects. Strategies to mitigate this include dosing optimization, antigen selection, and logic-gated CAR designs .

Immunosuppressive Tumor Microenvironment

Solid tumors are often resistant to CAR T cells due to an immunosuppressive microenvironment. Combinations with senescence-inducing agents, immune agonists, or other immunotherapies may be necessary to overcome this resistance .

Mitochondrial Resistance

The observation that senescent cancer cells are less primed for apoptosis is a significant challenge that may limit efficacy. Strategies to address this include combining CAR T cells with BH3 mimetics (drugs that neutralize anti-apoptotic proteins) or engineering "armored" CAR T cells that neutralize specific anti-apoptotic dependencies .

Long-Term Safety

While CAR T cells can persist for years, this also raises concerns about long-term immune effects, especially in older individuals with compromised immune systems. Long-term follow-up studies in humans will be essential to confirm safety and durability .

---

8. Conclusion

Senolytic CAR T cell therapy represents a paradigm shift in treating age-related diseases and cancer. By harnessing the power of engineered immune cells to selectively eliminate senescent cells, this approach offers a durable, potentially prophylactic intervention that could dramatically improve healthspan and longevity. The identification of uPAR as a universal senescence marker has enabled the development of CAR T cells that can be applied across diverse pathological contexts, from metabolic syndrome to cancer.

The preclinical evidence is compelling: a single dose of uPAR CAR T cells can rejuvenate metabolic function in aged mice and prevent age-related decline when administered early in life. Clinical translation is already underway, with logic-gated CAR NK cells showing promising efficacy in AML and innovative delivery platforms simplifying manufacturing.

Several challenges remain, including managing off-target toxicity, overcoming tumor microenvironment resistance, and addressing the mitochondrial resistance mechanisms that limit apoptosis in senescent cancer cells. However, the living drug nature of CAR T cells combined with the universal relevance of cellular senescence positions this therapeutic modality as one of the most exciting frontiers in modern medicine, with the potential to redefine our approach to aging and chronic disease.

---

9. Key Published Works and Resources

Landmark Study: Amor C, Feucht J, Leibold J, et al. Senolytic CAR T cells reverse senescence-associated pathologies. Nature. 2020;583(7814):127-132

Durability Study: Amor C, Fernández-Maestre I, Chowdhury S, et al. Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction. Nat Aging. 2024;4(3):336-349

Mechanisms: Menendez JA, Lupu R, Martin-Castillo B, et al. Mitochondrial priming in therapy-induced senescence: implications for CAR-T/NK immunosenolytic therapy. Front Immunol. 2025;16:1695244

Clinical Translation: Senti Biosciences. SENTI-202 Logic-Gated CAR NK Cell Therapy for AML. Investor Presentation, October 2025

EU Research Project: CARsen Project. Senolytic CAR T cells as novel therapeutic concept for solid tumors and senescence-associated diseases. EBERHARD KARLS UNIVERSITAET TUEBINGEN

Delivery Innovation: Zhang Z, Ma B, Li B, et al. Cardiolipin-mimic lipid nanoparticles without antibody modification delivered senolytic in-vivo CAR-T therapy for inflamm-aging. bioRxiv. 2025